German Anguiano Torres (@gerantomd) header
German Anguiano Torres (@gerantomd) profile picture

Medico Internista, Cardiológo Clínico, Master en Teoría Cardiovascular, FSIAC. Los comentarios vertidos aquí son a título propio

México
Joined March 2010
Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)Photo by German Anguiano Torres (@gerantomd)
German Anguiano Torres retweeted
🫀 AHA 2026 | The Trials That Matter From ZEUS and Lp(a)HORIZON to SYNCHRONIZE-CVOT, WATCH-LV and AI-ECHO: major lessons in prevention, cardiometabolic care and AI. What worked? What didn’t? What’s next? 👇 Key takeaways in one infographic. #AHA26 #Cardiology #HeartFailure #AI
🤖 Made with AI
1
48
1
138
8,608
German Anguiano Torres retweeted
In patients with suspected acute coronary syndrome without myocardial infarction, routine CT coronary angiography did not result in a lower incidence of myocardial infarction or death from a cardiac cause than standard care. Full TARGET-CTCA trial results and Research Summary: nej.md/4wH7Yk7 #ESCCongress
6
46
3
191
29,495
German Anguiano Torres retweeted
Presented at #ScientificSessions26: In patients with atrioventricular block, left bundle-branch pacing resulted in a lower incidence of a composite of death, hospitalization for heart failure, or pacing-induced cardiomyopathy than right ventricular pacing. Full OptimPacing trial results: nej.md/4favsI9 @AHAScience
8
147
19
391
68,215
🚨 #AHA26 #LBCT: ISCHEMIA-EXTEND 🫀 5,179 pts with stable CAD & ≥moderate ischemia (23% women). ⏳Median 9-yr follow-up ⚖️ Invasive vs conservative no difference in: 🔹All-cause death: HR 0.97 (95% CI 0.86–1.09) ❤️ CV death: HR 0.88 (0.75–1.02) 🔹 Non-CV death: HR 1.18 (0.96–1.45) 🎯 GDMT remains foundational. Routine invasive care does NOT improve overall survival. Shared decision-making matters! @JAMA_current #ScientificSessions26 🔗
2
71
4
185
10,562
German Anguiano Torres retweeted
OPTIMAL-STROKE results presented at #ScientificSessions26 Targeting a systolic BP of less than 120 mm Hg lowered the incidence of major cardiovascular events compared with targeting a systolic BP of less than 140 mm Hg in patients with previous ischemic stroke or transient ischemic attack.
3
31
1
93
3,906
German Anguiano Torres retweeted
Today #AHA26 and @NEJM the 2 big trials of secondary prevention of heart disease with an IL-6 antibody and Lp(a) antisense oligonucleotide. No beneficial effect, overall and across all subgroups nejm.org/doi/full/10.1056/NE… nejm.org/doi/full/10.1056/NE…
30
95
11
350
56,342
German Anguiano Torres retweeted
Lp(a) HORIZON trial: Pelacarsen 80 mg SC monthly yielded similar 4-component MACE rates vs. placebo over a median follow-up of 57 months in patients with established cardiovascular disease and elevated Lp(a), showing neutral effects on cardiovascular outcomes. Download slides here: clinicaltrialresults.org/wp-…
10
37
110
11,351
German Anguiano Torres retweeted
Presented at #ScientificSessions26: In older adults with at least two chronic conditions and no known atherosclerotic cardiovascular disease, statin discontinuation was noninferior to continuation for a composite of myocardial infarction, stroke, or death at 2 years. Full STREAM trial results: nej.md/47U1X9N @AHAScience
51
136
90
576
394,913
German Anguiano Torres retweeted
Presented at #ScientificSessions26: In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, ziltivekimab decreased interleukin-6 levels but did not result in fewer cardiovascular events than placebo. Full ZEUS trial results: nej.md/3UCOqQC @AHAScience
9
49
5
118
15,627
German Anguiano Torres retweeted
Presented at #ScientificSessions26: Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n @AHAScience
15
120
31
338
53,573
We know elevated Lp(a) marks inherited CV risk. Saturday, HORIZON asks the next question: if we specifically lower Lp(a), do CV outcomes improve? Biomarker --> intervention --> outcome. This one matters. But, what will it tell us? #ScientificSessions26 @AHAScience
🤖 Made with AI
1
7
19
1,254
Can smartwatch AI detect LV dysfunction? WATCH-LV may help answer that Monday. My next question: who receives the signal, acts on it and closes the loop? SIGNAL → WORKFLOW → ACTION → OUTCOME. #ScientificSessions26 @AHAScience
🤖 Made with AI
1
2
57
Obesity trials should not stop at the scale. Monday, SYNCHRONIZE-CVOT asks whether survodutide changes CV outcomes in people with obesity. Weight matters, but health is the outcome I’m watching. #ScientificSessions26 @AHAScience
🤖 Made with AI
1
2
5
249
When might stopping a preventive medicine be reasonable? STREAM studies statin discontinuation in multimorbid older adults without CVD. I’ll be watching time to benefit, function, burden and patient priorities. #ScientificSessions26 @AHAScience
🤖 Made with AI
1
1
3
107
German Anguiano Torres retweeted
No te puedes perder este Consenso Mexicano de Hipertensión 2026 . Súper práctico y útil. grehta.org/formacion-academi… @ANCAM_MEXICO @AncisssteMx @AMPAC2012 @SSalud_mx
2
3
161
German Anguiano Torres retweeted
In this new State-of-the-art paper, the authors review the evidence and guideline support for intracoronary imaging in contemporary clinical practice, and outline a modern, imaging-driven approach to PCI planning. eurointervention.pcronline.c…
3
97
2
256
16,665
German Anguiano Torres retweeted
Cardiogenic shock is associated with high early mortality. Prompt revascularization in infarct-related cardiogenic shock improves outcomes, and mechanical circulatory support may reduce mortality in specific groups. Read the Review Article “Cardiogenic Shock” by Holger Thiele, MD (@thiele_holger), and Christian Hassager, MD, from Heart Center Leipzig at Leipzig University, Leipzig Heart Science, Rigshospitalet, and the University of Copenhagen (@koebenhavns_uni): nej.md/49ohKyV
7
188
4
537
54,322
German Anguiano Torres retweeted
📚Ya está disponible la actualización 2025 de la Guía ESC 2019 sobre el manejo de las dislipemias. 🎯 Actualiza los objetivos terapéuticos 💊 Refuerza y optimiza las estrategias de tratamiento ➡️ Mejora el abordaje integral del riesgo cardiovascular 📄 Puedes descargarla aquí: secardiologia.es/publicacion… @VDelgadoGarcia
4
317
2
1,109
56,088
German Anguiano Torres retweeted
🔥🫀 Inflammation is no longer a hypothesis—it’s a therapeutic target The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease marks a turning point: inflammation is now recognized as a causal, measurable, and actionable driver of cardiovascular risk, not just a bystander . 🧠 Key paradigm shift Even in statin-treated patients with optimal LDL-C, residual inflammatory risk—best captured by high-sensitivity C-reactive protein (hsCRP)—strongly predicts recurrent events and cardiovascular death. In fact, post-statin hsCRP is often more prognostic than LDL-C itself. 📏 Measure what you want to treat The statement makes a bold recommendation: 👉 Near-universal hsCRP screening in both primary and secondary prevention. hsCRP <1 mg/L → low risk 1–3 mg/L → intermediate risk 3 mg/L → high inflammatory risk Persistently elevated hsCRP (>2 mg/L) identifies patients who remain vulnerable despite guideline-directed therapy. 💊 Anti-inflammatory therapies: what works (and what doesn’t) ❌ Broad immunosuppression failed (e.g. methotrexate in CIRT). ✅ Targeted inflammation inhibition works: Canakinumab (CANTOS) proved the inflammation hypothesis—reducing events without lowering LDL-C. Low-dose colchicine (0.5 mg/day) reduced recurrent CV events by ~25% and is now FDA-approved for secondary prevention. 🚧 New frontiers: IL-6 inhibition (ziltivekimab, clazakizumab) in CKD, HFpEF, ACS—results expected soon. 🧘‍♂️ Lifestyle is anti-inflammatory medicine Mediterranean/DASH diets 🥗, omega-3 intake 🐟, exercise 🏃‍♀️, weight control, and smoking cessation are explicitly framed as anti-inflammatory interventions, not just “healthy habits.” 🖼️ Imaging: promising, not ready Advanced imaging of vascular inflammation (e.g. perivascular fat attenuation index) is exciting—but not yet for routine clinical use. 🔮 Bottom line Atherosclerosis is an inflammatory disease with lipid involvement. The time has come to treat cholesterol and inflammation—with biomarkers, lifestyle, and targeted therapies—moving cardiovascular prevention into a new era 🚀
15
295
8
853
51,190
German Anguiano Torres retweeted
🆕 Reparación mitral percutánea borde a borde en la insuficiencia mitral secundaria: a quién, cuándo y por qué. 📕 EuroIntervention 🔓 Resumen del artículo en cardioteca.com/hemodinamica-…
11
52
3,491